Nicolás Montesdeoca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nicolás Montesdeoca has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Karges
Ruhr University Bochum Universitätsstraße 150
6 shared publications - Félix Grosjean
Microbiology Bioorganic and Macromolecular Chemistry Faculté de Pharmacie Université Libre de Bruxelles Brussels Belgium
2 shared publications - Gilles Berger
Microbiology Bioorganic and Macromolecular Chemistry Faculté de Pharmacie Université Libre de Bruxelles Brussels Belgium
2 shared publications Marta López
School of Chemical Sciences and Engineering Yachay Tech University San Miguel de Urcuquí Ecuador
2 shared publicationsA Jeong
Boschstraße 12, 69469
1 shared publicationAkihiko Furukawa
Z. B. dem verbilligten Bezug der Angewandten Chemie, sowie den Antrag auf Mitglied-schaft finden Sie unter www.gdch.de oder kçnnen Sie bei der GDCh, Postfach 900440, D-60444 Frankfurt am Main, anfordern
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by Wiley in Angewandte Chemie International Edition
- p. e3172220
Activation of Metal Complexes With Ultrasound Waves for Targeted Anticancer Therapy
Ultrasound technology has undergone a fundamental paradigm shift, evolving from a conventional diagnostic instrument into a sophisticated platform for non‐invasive, site‐specific cancer therapy. By harnessing the inverse piezoelectric effect, ultrasound generates mechanical waves that trigger acoustic cavitation in liquid media, producing localized hotspots of extreme temperature and pressure that can be exploited to activate rationally designed metal complexes through distinct and complementary mechanisms. This review provides a comprehensive analysis of two primary therapeutic modalities enabled by this approach. In sonodynamic therapy, metal centers function as sonosensitizers, generating cytotoxic reactive oxygen species through sonoluminescence‐mediated energy transfer. In ultrasound‐induced ligand release, the mechanochemical potential of metallocenes and coordination polymers is exploited, whereby cavitation‐induced shear forces drive heterolytic metal–ligand bond scission to achieve spatially controlled release of bioactive payloads and catalysts. A defining advantage of this platform over light‐based therapeutic modalities is its capacity to reach deep‐seated tumors. By synthesizing current structure–activity relationships and mechanistic understanding, this review establishes a rational design roadmap for next‐generation smart metal‐based prodrugs and delineates the critical challenges, including acoustic parameter standardization, long‐term metal fragment toxicology, and translational modeling fidelity, that must be addressed to advance this emerging field toward clinical application.
- 14 September 2026
- Published by Wiley in Angewandte Chemie International Edition
- p. e3172220
Open AccessActivation of Metal Complexes With Ultrasound Waves for Targeted Anticancer Therapy
Ultrasound technology has undergone a fundamental paradigm shift, evolving from a conventional diagnostic instrument into a sophisticated platform for non‐invasive, site‐specific cancer therapy. By harnessing the inverse piezoelectric effect, ultrasound generates mechanical waves that trigger acoustic cavitation in liquid media, producing localized hotspots of extreme temperature and pressure that can be exploited to activate rationally designed metal complexes through distinct and complementary mechanisms. This review provides a comprehensive analysis of two primary therapeutic modalities enabled by this approach. In sonodynamic therapy, metal centers function as sonosensitizers, generating cytotoxic reactive oxygen species through sonoluminescence‐mediated energy transfer. In ultrasound‐induced ligand release, the mechanochemical potential of metallocenes and coordination polymers is exploited, whereby cavitation‐induced shear forces drive heterolytic metal–ligand bond scission to achieve spatially controlled release of bioactive payloads and catalysts. A defining advantage of this platform over light‐based therapeutic modalities is its capacity to reach deep‐seated tumors. By synthesizing current structure–activity relationships and mechanistic understanding, this review establishes a rational design roadmap for next‐generation smart metal‐based prodrugs and delineates the critical challenges, including acoustic parameter standardization, long‐term metal fragment toxicology, and translational modeling fidelity, that must be addressed to advance this emerging field toward clinical application.
- Open Access
- 9 September 2026
- Published by Wiley in Angewandte Chemie
- p. e3172220
Aktivierung von Metallkomplexen durch Ultraschallwellen für eine gezielte Krebstherapie
ZUSAMMENFASSUNG: Die Ultraschalltechnologie hat einen grundlegenden Paradigmenwechsel durchlaufen und sich von einem herkömmlichen Diagnosegerät zu einer hochentwickelten Plattform für die nichtinvasive, ortsspezifische Krebstherapie weiterentwickelt. Durch die Nutzung des inversen piezoelektrischen Effekts erzeugt Ultraschall mechanische Wellen, die in flüssigen Medien akustische Kavitation auslösen und so lokalisierte Hotspots mit extremen Temperaturen und Drücken erzeugen, die genutzt werden können, um rational entworfene Metallkomplexe über unterschiedliche und sich ergänzende Mechanismen zu aktivieren. Dieser Übersichtsartikel bietet eine umfassende Analyse zweier primärer therapeutischer Modalitäten, die durch diesen Ansatz ermöglicht werden. In der sonodynamischen Therapie fungieren Metallzentren als Sonosensibilisatoren und erzeugen durch sonolumineszenz‐vermittelte Energieübertragung zytotoxische reaktive Sauerstoffspezies. Bei der ultraschallinduzierten Ligandenfreisetzung wird das mechanochemische Potenzial von Metallocenen und Koordinationspolymeren genutzt, wobei kavitationsinduzierte Scherkräfte die heterolytische Spaltung der Metall‐Liganden‐Bindung vorantreiben, um eine räumlich kontrollierte Freisetzung von bioaktiven Wirkstoffen und Katalysatoren zu erreichen. Ein entscheidender Vorteil dieser Plattform gegenüber lichtbasierten Therapieformen ist ihre Fähigkeit, tiefliegende Tumore zu erreichen. Durch die Zusammenführung aktueller Struktur‐Wirkungs‐Beziehungen und mechanistischer Erkenntnisse erstellt dieser Übersichtsartikel einen rationalen Leitfaden für die Entwicklung intelligenter Prodrugs auf Metallbasis der nächsten Generation und skizziert die entscheidenden Herausforderungen, darunter die Standardisierung akustischer Parameter, die Langzeittoxikologie von Metallfragmenten und die Genauigkeit translationaler Modellierung, die bewältigt werden müssen, um dieses aufstrebende Forschungsgebiet in Richtung klinischer Anwendung voranzubringen.
- 9 September 2026
- Published by Wiley in Angewandte Chemie
- p. e3172220
Open AccessAktivierung von Metallkomplexen durch Ultraschallwellen für eine gezielte Krebstherapie
ZUSAMMENFASSUNG: Die Ultraschalltechnologie hat einen grundlegenden Paradigmenwechsel durchlaufen und sich von einem herkömmlichen Diagnosegerät zu einer hochentwickelten Plattform für die nichtinvasive, ortsspezifische Krebstherapie weiterentwickelt. Durch die Nutzung des inversen piezoelektrischen Effekts erzeugt Ultraschall mechanische Wellen, die in flüssigen Medien akustische Kavitation auslösen und so lokalisierte Hotspots mit extremen Temperaturen und Drücken erzeugen, die genutzt werden können, um rational entworfene Metallkomplexe über unterschiedliche und sich ergänzende Mechanismen zu aktivieren. Dieser Übersichtsartikel bietet eine umfassende Analyse zweier primärer therapeutischer Modalitäten, die durch diesen Ansatz ermöglicht werden. In der sonodynamischen Therapie fungieren Metallzentren als Sonosensibilisatoren und erzeugen durch sonolumineszenz‐vermittelte Energieübertragung zytotoxische reaktive Sauerstoffspezies. Bei der ultraschallinduzierten Ligandenfreisetzung wird das mechanochemische Potenzial von Metallocenen und Koordinationspolymeren genutzt, wobei kavitationsinduzierte Scherkräfte die heterolytische Spaltung der Metall‐Liganden‐Bindung vorantreiben, um eine räumlich kontrollierte Freisetzung von bioaktiven Wirkstoffen und Katalysatoren zu erreichen. Ein entscheidender Vorteil dieser Plattform gegenüber lichtbasierten Therapieformen ist ihre Fähigkeit, tiefliegende Tumore zu erreichen. Durch die Zusammenführung aktueller Struktur‐Wirkungs‐Beziehungen und mechanistischer Erkenntnisse erstellt dieser Übersichtsartikel einen rationalen Leitfaden für die Entwicklung intelligenter Prodrugs auf Metallbasis der nächsten Generation und skizziert die entscheidenden Herausforderungen, darunter die Standardisierung akustischer Parameter, die Langzeittoxikologie von Metallfragmenten und die Genauigkeit translationaler Modellierung, die bewältigt werden müssen, um dieses aufstrebende Forschungsgebiet in Richtung klinischer Anwendung voranzubringen.
- Open Access
- 10 March 2026
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 13 (9) , 3986-4004
Synthesis of Ananikov-type N-heterocyclic carbene golden synthons as ferroptosis inducing anticancer agents
A new generation of backbone-functionalized NHC–gold( i ) complexes reveals ferroptosis through comprehensive mechanistic and biological investigation.
- 10 March 2026
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 13 (9) , 3986-4004
Open AccessSynthesis of Ananikov-type N-heterocyclic carbene golden synthons as ferroptosis inducing anticancer agents
A new generation of backbone-functionalized NHC–gold( i ) complexes reveals ferroptosis through comprehensive mechanistic and biological investigation.
- Open Access
- 14 December 2024
- Published by Springer Nature in JBIC Journal of Biological Inorganic Chemistry
- Vol. 30 (1) , 53-60
Shift of cell-death mechanisms in primary human neutrophils with a ruthenium photosensitizer
Primary human neutrophils are the most abundant human white blood cells and are central for innate immunity. They act as early responders at inflammation sites, guided by chemotactic gradients to find infection or inflammation sites. Neutrophils can undergo both apoptosis as well as NETosis. NETosis is a form of neutrophil cell death that releases chromatin-based extracellular traps (NETs) to capture and neutralize pathogens. Understanding or controlling the balance between these cell-death mechanisms is crucial. In this study, the chemical synthesis and biologic assessment of a ruthenium complex as a light-activated photosensitizer that creates reactive oxygen species (ROS) in primary human neutrophils is reported. The ruthenium complex remains non-toxic in the dark. However, upon exposure to blue light at 450 nm, it exhibits potent cytotoxic effects in both cancerous and non-cancerous cell lines. Interestingly, the metal complex shifts the cell-death mechanism of primary human neutrophils from NETosis to apoptosis. Cells irradiated directly by the light source immediately undergo apoptosis, whereas those further away from the light source perform NETosis at a slower rate. This indicates that high ROS levels trigger apoptosis and lower ROS levels NETosis. The ability to control the type of cell death undergone in primary human neutrophils could have implications in managing acute and chronic infectious diseases. Graphical
- 14 December 2024
- Published by Springer Nature in JBIC Journal of Biological Inorganic Chemistry
- Vol. 30 (1) , 53-60
Open AccessShift of cell-death mechanisms in primary human neutrophils with a ruthenium photosensitizer
Primary human neutrophils are the most abundant human white blood cells and are central for innate immunity. They act as early responders at inflammation sites, guided by chemotactic gradients to find infection or inflammation sites. Neutrophils can undergo both apoptosis as well as NETosis. NETosis is a form of neutrophil cell death that releases chromatin-based extracellular traps (NETs) to capture and neutralize pathogens. Understanding or controlling the balance between these cell-death mechanisms is crucial. In this study, the chemical synthesis and biologic assessment of a ruthenium complex as a light-activated photosensitizer that creates reactive oxygen species (ROS) in primary human neutrophils is reported. The ruthenium complex remains non-toxic in the dark. However, upon exposure to blue light at 450 nm, it exhibits potent cytotoxic effects in both cancerous and non-cancerous cell lines. Interestingly, the metal complex shifts the cell-death mechanism of primary human neutrophils from NETosis to apoptosis. Cells irradiated directly by the light source immediately undergo apoptosis, whereas those further away from the light source perform NETosis at a slower rate. This indicates that high ROS levels trigger apoptosis and lower ROS levels NETosis. The ability to control the type of cell death undergone in primary human neutrophils could have implications in managing acute and chronic infectious diseases. Graphical
- Open Access
- 3 May 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (32) , e202400217
Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates
Cancer is one of the deadliest diseases worldwide. Chemotherapy remains one of the most dominant forms for anticancer treatment. Despite their clinical success, the used chemotherapeutic agents are associated with severe side effect and pharmacological limitations. To overcome these drawbacks there is a need for the development of new types of chemotherapeutic agents. Herein, the chemical synthesis and biological evaluation of dinuclear rhenium(I) complexes as potential chemotherapeutic drug candidates are proposed. The metal complexes were found to be internalized by an energy dependent endocytosis pathway, primary accumulating in the mitochondria. The rhenium(I) complexes demonstrated to induce cell death against a variety of cancer cells in the micromolar range through apoptosis. The lead compound showed to eradicate a pancreatic carcinoma multicellular tumor spheroid at micromolar concentrations.
- 3 May 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (32) , e202400217
Open AccessDinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates
Cancer is one of the deadliest diseases worldwide. Chemotherapy remains one of the most dominant forms for anticancer treatment. Despite their clinical success, the used chemotherapeutic agents are associated with severe side effect and pharmacological limitations. To overcome these drawbacks there is a need for the development of new types of chemotherapeutic agents. Herein, the chemical synthesis and biological evaluation of dinuclear rhenium(I) complexes as potential chemotherapeutic drug candidates are proposed. The metal complexes were found to be internalized by an energy dependent endocytosis pathway, primary accumulating in the mitochondria. The rhenium(I) complexes demonstrated to induce cell death against a variety of cancer cells in the micromolar range through apoptosis. The lead compound showed to eradicate a pancreatic carcinoma multicellular tumor spheroid at micromolar concentrations.
- Open Access
- 4 May 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (21)
Graphisches Inhaltsverzeichnis: Angew. Chem. 21/2023
- 4 May 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (21)
Open AccessGraphisches Inhaltsverzeichnis: Angew. Chem. 21/2023
- Open Access
- 6 August 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 11355-11381
Inhibitors of lipogenic enzymes as a potential therapy against cancer
Cancer cells rely on several metabolic pathways such as lipid metabolism to meet the increase in energy demand, cell division, and growth and successfully adapt to challenging environments. Fatty acid synthesis is therefore commonly enhanced in many cancer cell lines. Thus, relevant efforts are being made by the scientific community to inhibit the enzymes involved in lipid metabolism to disrupt cancer cell proliferation. We review the rapidly expanding body of inhibitors that target lipid metabolism, their side effects, and current status in clinical trials as potential therapeutic approaches against cancer. We focus on their molecular, biochemical and structural properties, selectivity and effectiveness and discuss their potential role as antitumor drugs.
- 6 August 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 11355-11381
Open AccessInhibitors of lipogenic enzymes as a potential therapy against cancer
Cancer cells rely on several metabolic pathways such as lipid metabolism to meet the increase in energy demand, cell division, and growth and successfully adapt to challenging environments. Fatty acid synthesis is therefore commonly enhanced in many cancer cell lines. Thus, relevant efforts are being made by the scientific community to inhibit the enzymes involved in lipid metabolism to disrupt cancer cell proliferation. We review the rapidly expanding body of inhibitors that target lipid metabolism, their side effects, and current status in clinical trials as potential therapeutic approaches against cancer. We focus on their molecular, biochemical and structural properties, selectivity and effectiveness and discuss their potential role as antitumor drugs.
- Open Access
- 19 February 2019
- Published by Clinical Biotec S.L. in Bionatura
- Vol. 02 (Bionatura )
Synthesis of new C75 derivatives, Fatty Acid Synthase inhibitors with cytotoxic properties
The fatty-acid synthase (FAS) is the key enzyme that executes de novo fatty acid synthesis and is overexpressed in some human cancer tissues. C75 is a synthetic FAS inhibitor, which produces the death of cancer cells. In this work, we synthesized three derivatives of C75, two homologs with 1 and 2 carbons more in the beta position of the lactone and the other one with a change in the elongation of the aliphatic chain in gamma position from 8 to 15 carbons. The results from FAS inhibition and cytotoxic properties suggest that the performed changes in the derivatives decrease their activity.
- 19 February 2019
- Published by Clinical Biotec S.L. in Bionatura
- Vol. 02 (Bionatura )
Open AccessSynthesis of new C75 derivatives, Fatty Acid Synthase inhibitors with cytotoxic properties
The fatty-acid synthase (FAS) is the key enzyme that executes de novo fatty acid synthesis and is overexpressed in some human cancer tissues. C75 is a synthetic FAS inhibitor, which produces the death of cancer cells. In this work, we synthesized three derivatives of C75, two homologs with 1 and 2 carbons more in the beta position of the lactone and the other one with a change in the elongation of the aliphatic chain in gamma position from 8 to 15 carbons. The results from FAS inhibition and cytotoxic properties suggest that the performed changes in the derivatives decrease their activity.